An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
NCT02226458 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2022-01-21
Summary
The investigators hypothesize that EPI-743 may provide clinical benefit to children with Autism Spectrum Disorder.
Conditions
Interventions
- DRUG
-
EPI-743
Sponsors & Collaborators
-
Edison Pharmaceuticals Inc
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 3 Years
- Max Age
- 14 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-10-31
- Primary Completion
- 2015-11-30
- Completion
- 2016-01-31
More Related Trials
-
Efficacy and Safety of Functional Neurogenesis Stimulation Therapy in Children With Autism Spectrum Disorder (ASD)
NCT07276555 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
NCT06951854 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
NCT02140112 ·Status: TERMINATED ·Phase: PHASE2
-
Intranasal Oxytocin and Learning in Autism
NCT02090829 ·Status: WITHDRAWN ·Phase: PHASE2
-
Intranasal Vasopressin Treatment in Children With Autism
NCT03204786 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
NCT01931033 ·Status: COMPLETED ·Phase: NA
-
TSO in Pediatric Autistic Spectrum Disorders
NCT01734941 ·Status: TERMINATED ·Phase: PHASE2
-
Safety of L1-79 in Adolescent and Adult Males With Autism
NCT02947048 ·Status: COMPLETED ·Phase: PHASE2
-
Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY)
NCT01256060 ·Status: COMPLETED ·Phase: PHASE2
-
Triadic Interactions of Families With Autism and Oxytocin
NCT01912378 ·Status: WITHDRAWN ·Phase: PHASE1
-
Trichuris Suis Ova in Autism Spectrum Disorders
NCT01040221 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Finding Study of Pioglitazone in Children With Autism Spectrum Disorders (ASD) (PIO)
NCT01205282 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of Vayarin in Children With Autism and Comorbid Attention Deficit Hyperactivity Disorder (ADHD)
NCT03115671 ·Status: COMPLETED ·Phase: NA
-
Intranasal Oxytocin and Learning in Autism
NCT01417026 ·Status: COMPLETED ·Phase: PHASE2
-
An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)
NCT02222285 ·Status: COMPLETED ·Phase: NA
-
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?
NCT02348125 ·Status: UNKNOWN ·Phase: PHASE1
-
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
NCT05067582 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder
NCT01970345 ·Status: TERMINATED ·Phase: PHASE2
-
Therapeutic Issues for Autism
NCT03887754 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Clinical Study on Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Childhood Autism
NCT07243561 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders
NCT02757066 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
NCT01944046 ·Status: COMPLETED ·Phase: PHASE2
-
Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
NCT04745026 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Combined Medication and Behavioral Treatment for ASD & ADHD
NCT03242772 ·Status: TERMINATED ·Phase: PHASE2
-
Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response
NCT02414451 ·Status: WITHDRAWN ·Phase: NA